Sanofi has signed a collaboration agreement with Innate Pharma giving it access to the latter’s technology to to create new Antibody Drug Conjugates.
ADCs combine monoclonal antibodies with a payload of deadly chemotherapy for release inside the targeted cell, the idea being to boost effectiveness of treatment while preventing healthy tissues from harm.
The groups plan to combine Sanofi’s anti-tumor antibodies with Innate’s technology for conjugating cytotoxic compounds, opening the gate to next-generation ADCs “with a potentially improved therapeutic index for patients with cancer”, said Innate chief Hervé Brailly.
Under the deal, Sanofi will evaluate site-specific payload conjugation to enhance ADC pharmacokinetics, efficacy and safety, and also has the option to enter into a licencing agreement with Innate on this technology.
Further terms were not disclosed.